Click to Skip Ad
Closing in...



Pfizer

Coronavirus Mutation

Pfizer and BioNTech prove their COVID vaccine works on new mutations

January 8th, 2021

Pfizer and BioNTech announced they completed testing that shows the key mutation present on the UK and South African coronavirus strains would not create resistance to the vaccine. Researchers tested sera containing antibodies from 20 volunteers who received the vaccine during the Phase 3 trial and found that the coronavirus-specific proteins neutralized the key mutation. …

Coronavirus Vaccine Pfizer

Pfizer has even more good news today about its coronavirus vaccine

November 10th, 2020

Pfizer CEO Dr. Albert Bourla said in an interview there are “no safety concerns” for the BioNTech coronavirus vaccine that has shown effecacy of 90%, according to interim Phase 3 results. The CEO explained that the company will apply for emergency use authorizations once the safety data satisfy its requirements, but it’s up to the …

Coronavirus Vaccine

The first Phase 3 coronavirus vaccine trial results are here – and they’re incredible

November 9th, 2020

The first interim results for one of the leading coronavirus vaccine candidates have arrived, showing incredibly promising efficacy results. According to the first batch of data, the Pfizer/BioNTech mRNA vaccine is 90% effective, a figure that’s significantly higher than initial estimates. Pfizer will have safety data available by the third week of November, at which …

Coronavirus Vaccine Update

These promising coronavirus vaccines could be approved sooner than expected – but not in the US

November 1st, 2020

The UK has accelerated the review of the three coronavirus vaccine frontrunners: AstraZeneca, Moderna, and Pfizer. The country’s government is conducting rolling reviews, which allow it to see data in real-time and potentially hasten emergency use approval for the vaccine candidates that prove to be safe and effective. The US FDA has strict requirements for …

Coronavirus Vaccine

We have to wait longer than expected for coronavirus vaccine trial results – but that might be great news

October 28th, 2020

Coronavirus vaccine candidate maker Pfizer was expected to release early efficacy results for Phase 3 in mid-October, ahead of the presidential election. That’s no longer the case, as the first efficacy data isn’t yet available. Pfizer, which is blinded to the study, awaits conclusions from an independent data and safety monitoring board. The first results …

Coronavirus Vaccine

We’re not getting a coronavirus vaccine before the election

October 17th, 2020

The company making the only coronavirus vaccine with a theoretical chance of being approved before the US presidential election made it clear such a timeline is unfeasible. Pfizer CEO Albert Bourla said his company might have the efficacy data this month, but the crucial safety data will not be available until the third week of …